Lyme Disease Vaccine Efficacy: Questions from the OspA Trial
The Lyme disease OspA vaccine demonstrated effectiveness in preventing certain early manifestations, but important questions remain regarding its overall efficacy.
This raises an important question: how effective was the Lyme disease vaccine across different clinical outcomes? Trial data suggest strong protection against confirmed erythema migrans, but more limited effectiveness for broader definitions of illness.
The OspA vaccine trial reported 78% efficacy in preventing culture-confirmed erythema migrans. However, the vaccine was only 48% effective in preventing what was defined as “possible Lyme disease.”
“Possible Lyme disease” included flu-like illness (fever, chills, fatigue, headache, joint or muscle aches) with serologic conversion or physician-diagnosed erythema migrans without laboratory confirmation, according to the LYMErix™ package insert.
Unanswered Questions from the Vaccine Trial
The trial did not evaluate whether the vaccine prevented later or more complex manifestations of Lyme disease, including neurologic involvement or post-treatment symptoms.
- Efficacy was lower in individuals who received only two doses
- Long-term protection beyond two years was not established
- Coverage of European Borrelia species (B. garinii, B. afzelii) was not evaluated
- Potential autoimmune mechanisms related to molecular mimicry were not fully addressed
Interpreting Vaccine Effectiveness
The difference in efficacy between confirmed erythema migrans and broader clinical definitions highlights the challenges of measuring vaccine performance in Lyme disease.
Protection against early localized infection does not necessarily indicate prevention of all disease manifestations.
Future Directions
A meta-analysis concluded that newer, multivalent OspA-based vaccines may offer broader protection against multiple Borrelia burgdorferi sensu lato strains.
Further research will be needed to determine whether next-generation vaccines address the limitations identified in earlier trials.
Clinical Perspective
These findings highlight the complexity of Lyme disease prevention and the challenges in developing a vaccine that protects against diverse clinical presentations.
Patients may benefit from review of tick bite prevention, understanding Lyme disease symptoms, and awareness of testing limitations when considering risk and prevention strategies.
References
- Zhao H et al. Safety and efficacy of OspA vaccine. J Infect Dev Ctries. 2017.
- FDA Package Insert – LYMErix™
- Steere AC et al. OspA vaccine trial. N Engl J Med.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
why is band 34 not put back on diagnosis?’
The CDC has not called for another meeting to discuss bands since 1994. The 31 and 34 was not considered for the criteria as the CDC expected a vaccine would lead to positive tests. The vaccine was pulled nearly 20 years ago.